杂志简称：cancer manag res
中文译名：《癌症管理与研究》
收录属性：scie（2024版）, 目次收录（知网）,英文期刊,
自引率：3.30%
投稿方向：医学、oncology肿瘤学
SCI/E期刊基本信息
出版周期：不定期 地区：新西兰
中科院分区：3区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：OA期刊
国际标准刊号：ISSN 1179-1322；EISSN 1179-1322
杂志语言：英语
出版国家：新西兰
杂志官网 联系方式
出版地址：PO BOX 300-008,ALBANY,NEW ZEALAND,AUCKLAND,0752
杂志邮箱：
投稿网址：https://www.dovepress.com/submit-step-1.php
杂志官方网址：https://www.dovepress.com/cancer-management-and-research-journal
出版商网址：http://www.dovepress.com
杂志投稿要求
投稿须知【杂志社官方网站信息】
Cancer Management and Research
Aims and Scope
Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients.
Cancer Management and Research will no longer consider meta-analyses for publication.
Specific topics covered in the journal include:
Epidemiology, detection and screening
Cellular research and biomarkers
Identification of biotargets and agents with novel mechanisms of action
Optimal clinical use of existing anticancer agents, including combination therapies
Radiation and surgery
Palliative care
Patient adherence, quality of life, satisfaction
The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.
When considering submission of a paper utilizing publicly-available data (e.g. SEER/GWAS/TCGA/GEO etc.), authors should ensure that such studies add significantly to the body of knowledge about a specific disease or relevant phenotype and that they are validated using the authors’ own data through replication in an independent sample set and functional follow-up. Bioinformatics studies should also conform to these criteria.
The journal does not consider case reports except in circumstances where they make a valuable contribution to the literature. Cell line studies must demonstrate thorough and rigorous protocols, and biomarker association studies must be supported by in vivo validations. Tissue microarray analyses and single nucleotide polymorphism (SNP) studies will not be considered.
Call For Papers
To see where Cancer Management and Research is indexed online view the Journal Metrics.
What is the advantage to you of publishing in Cancer Management and Research?
It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove Medical Press website.
Although Cancer Management and Research receives many papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Cancer Management and Research has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
Many authors have found that our peer reviewers’ comments substantially add to their final papers.
To recover our editorial and production costs, and continue to provide our content at no cost to readers, we charge authors or their institution a publication processing fee.
PubMed
Cancer Management and Research is indexed on PubMed Central (title abbreviation Cancer Manag Res). All published papers in this journal are submitted to PubMed for indexing straight away.
Become a Favored Author and receive real benefits
If you haven't already joined the Dove Medical Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal coordinator for your paper, as well as a discount on the publication processing fee. Click here to go through to the Favored Author signup page, you'll just need to supply the working title of your next paper and when you intend to submit by.
Yours sincerely
Dr Kenan Onel
Editor-in-Chief
Cancer Management and Research
Email: Editor-in-Chief
Author Guidelines
In this section you will find information on the entire submission process for Dovepress Journals. This includes how to format the paper, the language guidelines, referencing, the use of data & clinical trials and the acceptance process. These resources ensure the quality of the journal submissions and that the articles have the best chance of acceptance.
A summary of some of these sections are:
Manuscript preparation
This provides guidelines to the formatting requirements for a submission to Dove Medical Press, with instructions for formatting the document (margins, spacing, etc) and the text (spelling, abbreviations, etc).
Manuscript template
The template provided at this link can be used to ensure that the manuscript meets Dove specifications for formatting and structure of the text. The template can be downloaded and saved to your computer.
Manuscript structure
This section contains a detailed breakdown of each section that the manuscript will contain, as well as all disclosures and acknowledgements that are required by Dove Medical Press. The section also includes criteria for inclusion in the author list.
Figures and tables
This contains specifications for the formatting of figures and tables, including technical requirements such as file types and naming, and graphic requirements such as font size and image resolution.
Clinical trial registration
This provides a clear definition that authors may use to determine if their study will be considered a clinical trial. The section sets out Dove’s requirements for registration of any clinical trial involving human subjects.